A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers Meeting Abstract
| Authors: | Hong, D. S.; Younes, A.; Fayad, L.; Fowler, N. H.; Hagemeister, F. B.; Mistry, R.; Nemunaitis, J. J.; Borad, M. J.; Bryce, A. H.; Yamashita, M.; Hughes, S. G.; Kwoh, T. J.; MacLeod, A. R.; Norris, D.; Baldwin, R.; Hung, G. N.; Monia, B. P.; Kurzrock, R. |
| Abstract Title: | A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419602619 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.8523 |
| Notes: | Meeting Abstract: 8523 -- Source: Wos |
